>
Switch to:

Opiant Pharmaceuticals ROE %

: 19.15% (As of Jun. 2021)
View and export this data going back to 2007. Start your Free Trial

ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. Opiant Pharmaceuticals's annualized net income attributable to common stockholders for the quarter that ended in Jun. 2021 was $6.74 Mil. Opiant Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Jun. 2021 was $35.17 Mil. Therefore, Opiant Pharmaceuticals's annualized ROE % for the quarter that ended in Jun. 2021 was 19.15%.

The historical rank and industry rank for Opiant Pharmaceuticals's ROE % or its related term are showing as below:

NAS:OPNT' s ROE % Range Over the Past 10 Years
Min: -200.02   Med: -5.32   Max: 45.22
Current: -3.19

-200.02
45.22

During the past 13 years, Opiant Pharmaceuticals's highest ROE % was 45.22%. The lowest was -200.02%. And the median was -5.32%.

NAS:OPNT's ROE % is ranked lower than
99.99% of the 275 Companies
in the Biotechnology industry.

( Industry Median: -68.79 vs. NAS:OPNT: -3.19 )

Opiant Pharmaceuticals ROE % Historical Data

The historical data trend for Opiant Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Dec18 Dec19 Dec20
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -200.02 45.22 -5.32

Opiant Pharmaceuticals Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.54 8.31 -7.73 -32.75 19.15

Competitive Comparison

For the Biotechnology subindustry, Opiant Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Opiant Pharmaceuticals ROE % Distribution

For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Opiant Pharmaceuticals's ROE % falls into.



Opiant Pharmaceuticals ROE % Calculation

Opiant Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2020 is calculated as

ROE %=Net Income attributable to Common Stockholders (A: Dec. 2020 )/( (Total Stockholders Equity (A: Dec. 2019 )+Total Stockholders Equity (A: Dec. 2020 ))/ count )
=-1.861/( (34.416+35.492)/ 2 )
=-1.861/34.954
=-5.32 %

Opiant Pharmaceuticals's annualized ROE % for the quarter that ended in Jun. 2021 is calculated as

ROE %=Net Income attributable to Common Stockholders (Q: Jun. 2021 )/( (Total Stockholders Equity (Q: Mar. 2021 )+Total Stockholders Equity (Q: Jun. 2021 ))/ count )
=6.736/( (33.986+36.356)/ 2 )
=6.736/35.171
=19.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Jun. 2021) net income attributable to common stockholders data. ROE % is displayed in the 30-year financial page.


Opiant Pharmaceuticals  (NAS:OPNT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %**(Q: Jun. 2021 )
=Net Income/Total Stockholders Equity
=6.736/35.171
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(6.736 / 45.036)*(45.036 / 60.3305)*(60.3305 / 35.171)
=Net Margin %*Asset Turnover*Equity Multiplier
=14.96 %*0.7465*1.7153
=ROA %*Equity Multiplier
=11.17 %*1.7153
=19.15 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %**(Q: Jun. 2021 )
=Net Income/Total Stockholders Equity
=6.736/35.171
=(Net Income /Pre-Tax Income) * (Pre-Tax Income/Operating Income) * (Operating Income/Revenue) * (Revenue/Total Assets) * (Total Assets/Total Stockholders Equity)
= (6.736 / 6.736) * (6.736 / 8.988) * (8.988 / 45.036) * (45.036 / 60.3305) * (60.3305 / 35.171)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.7494 * 19.96 % * 0.7465 * 1.7153
=19.15 %

Note: The net income attributable to common stockholders data used here is four times the quarterly (Jun. 2021) net income attributable to common stockholders data. The Revenue data used here is four times the quarterly (Jun. 2021) revenue data. The same rule applies to Pre-Tax Income and Operating Income.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Opiant Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Opiant Pharmaceuticals Business Description

Opiant Pharmaceuticals logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
233 Wilshire Blvd, Suite 280, Santa Monica, CA, USA, 90401
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.
Executives
Thomas Thomas T. director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Sinclair Michael director, 10 percent owner 86 GLOUCESTER PLACE LONDON XX W1U6HP
Collard Craig A director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Daly Richard J director 355 ALHAMBRA CIRCLE SUITE 1500 CORAL GABLES FL 33134
Macdougall Ann L. director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Silver Gabrielle Alison director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Gorman Brian other: General Counsel 233 WILSHIRE BLVD SUITE 280 SANTA MONICA CA 90401
Skolnick Phil officer: Chief Scientific Officer C/O DOV PHARMACEUTICAL, INC. 433 HACKENSACK AVENUE HACKENSACK NJ 07601
Crystal Roger director, 10 percent owner, officer: Chief Executive Officer 445 PARK AVE 10TH FL. NEW YORK NY 10022
Ellison Mark Jason Heath other: UK Managing Director C/O OPIANT PHARMACEUTICALS, INC. 201 SANTA MONICA BLVD., SUITE 500 SANTA MONICA CA 90401
Thompson Rahsaan other: General Counsel 233 WILSHIRE BOULEVARD SUITE 280 SANTA MONICA CA 90401
Mottiwala Aziz officer: Chief Commercial Officer 233 WILSHIRE BOULEVARD SUITE 280 SANTA MONICA CA 90401
Wolf Geoffrey 10 percent owner 445 PARK AVENUE 10TH FL. NEW YORK NY 10022
Pollack Kevin director, officer: See Remarks 150 RAINVILLE ROAD TARPON SPRINGS FL 34689
Meuse Joseph J director, 10 percent owner 211 FALMOUTH STREET WARRENTON VA 20186

Opiant Pharmaceuticals Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)